Multiple myeloma clinical trials

Explore recruiting multiple myeloma clinical trials.

Recruiting multiple myeloma studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Multiple myeloma trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A Single-Blind randomized trial of High-Dose versus Standard-Dose Inactivated Influenza Vaccine in Adult Patients Treated for an Hematological Cancer (Flu-Hemato-Rando study)

Belgium

Therapeutic confirmatory (Phase III) EU CTIS Study details

Venetoclax and Dexamethasone in translocation (11;14) positive relapsed and refractory multiple myeloma (VICTORIA)

Denmark

Therapeutic exploratory (Phase II) EU CTIS Study details

A Phase 2, single arm Multicenter, Study testing Mezigdomide, Carfilzomib, and Dexamethasone (480Kd) in Participants with Relapsed or Refractory Multiple Myeloma (RRMM). (MEZI-KD)

France

Therapeutic exploratory (Phase II) EU CTIS Study details

A Phase I/IIa Study of ODX (OsteoDex) in Multiple Myeloma

Sweden

Phase I and Phase II (Integrated)- Other EU CTIS Study details

A Phase 2, open-label, multicenter multi-cohort study to evaluate the efficacy and safety of anitocabtagene autoleucel in participants with newly diagnosed multiple myeloma

Spain

Therapeutic exploratory (Phase II) EU CTIS Study details

A Phase III, Multicenter, Open-Label, Randomized Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination with Pomalidomide and Dexamethasone (B-Pd) versus Pomalidomide plus Bortezomib and Dexamethasone (PVd) in Participants with Relapsed/Refractory Multiple Myeloma (DREAMM 8)

Czechia, Greece, Germany, Poland, France, Italy +1 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

Multiple myeloma trials by city

Multiple myeloma in Toronto Multiple myeloma in Vancouver Multiple myeloma in Montreal Multiple myeloma in Calgary Multiple myeloma in Edmonton Multiple myeloma in Ottawa Multiple myeloma in Winnipeg Multiple myeloma in Quebec City Multiple myeloma in Hamilton Multiple myeloma in Kitchener Multiple myeloma in London Multiple myeloma in Halifax Multiple myeloma in New York Multiple myeloma in Los Angeles Multiple myeloma in Chicago Multiple myeloma in Houston

Other conditions

Erectile dysfunction Enlarged prostate (BPH) Breast cancer Prostate cancer Lung cancer Non-small cell lung cancer Colorectal cancer Pancreatic cancer Ovarian cancer Melanoma Leukemia Lymphoma Bladder cancer Kidney cancer Liver cancer Glioblastoma Head and neck cancer Cervical cancer Endometrial cancer Gastric cancer Age-related macular degeneration Diabetic retinopathy Glaucoma Dry eye disease